Modern Covid booster produces a strong antibody response against Omicron

Moderna’s Covid-19 shot results in a strong anti-antibody response against the Omicron type of coronavirus, which appears to increase antibody levels beyond the third dose of Pfizer vaccine.

Biotech from Boston said its half-dose increase increased antibodies by 37 times, compared with people who had only received two doses, indicating a similar immune response as in the Delta vaccine. Two doses resulted in a lower effect, a decrease of 2.9 against Omicron, compared with the wild type of virus.

BioNTech and Pfizer have previously stated that their booster raises 25 antibody levels, although the studies may not be directly related. The pair are also preparing for the shooting of Omicron, which is said to be available by March.

But Stéphane Bancel, Moderna’s chief executive, said on Monday that Moderna would continue to invest in the Omicron-based vaccine, if needed in the future, and put it into clinical trials early next year.

“The dramatic increase in Covid-19 cases from the Omicron brand affects all of them.

Shares in Moderna rose 6 percent to $ 312 in New York’s initial sale.

The mRNA technology used by Moderna and Pfizer is fast and flexible, so it can be used to make the desired vaccine in weeks. But it would have to be tested in a hospital before it could be approved.

Stephen Hoge, President of Moderna, said: “It would be great and what you would like to do if it were needed.”

Moderna’s total dose of vaccine increased antibody levels beyond 83. Moderna said it is up to the regulatory agencies to consider whether the full amount could be of benefit to some people, perhaps those most at risk.

More than half of Moderna contains more messengerRNA – genetic codes that allow the body to make spike proteins and produce immune responses – beyond the full dose of Pfizer.

Working with scientists from the US National Institutes of Health, Moderna tested how antibodies from vaccinated individuals took 29 days in adulthood to respond to pseudovirus, which was designed to incorporate mutations observed in Omicron genes. The data will be printed in a pre-printed paper.

The company did not yet know the strength of the response but Hoge said the 29-day event was “encouraging” because the vaccine has dropped dramatically in recent years.

The results of this study are in line with the findings of the Ragon Institute in Boston last week, which showed a significantly lower antibody rate for Pfizer shooting than for Moderna, but when encouraged, both vaccines did well against Omicron.

The lab also found that the mRNA vaccine was more effective in promoting antibody responses than the Johnson & Johnson shot, which uses the same adenovirus platform as Oxford / AstraZeneca.